These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24903780)

  • 21. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
    Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N
    Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
    Emre M
    Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nootropes (cognition enhancers) and neuroprotectors].
    Vornin TA; Seredenin SB
    Eksp Klin Farmakol; 2007; 70(4):44-58. PubMed ID: 18078043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical treatment of cognitive disorders in Alzheimer's disease.
    Senin U; Cherubini A; Palumbo B; Mecocci P
    Funct Neurol; 1997; 12(3-4):211-2. PubMed ID: 9218980
    [No Abstract]   [Full Text] [Related]  

  • 26. Can we do better in developing new drugs for Alzheimer's disease?
    Gauthier S; Scheltens P
    Alzheimers Dement; 2009 Nov; 5(6):489-91. PubMed ID: 19896588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?
    Fischer A
    Neuropharmacology; 2014 May; 80():95-102. PubMed ID: 24486385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease.
    Farlow MR
    Lancet Neurol; 2009 Jan; 8(1):22-3. PubMed ID: 19042160
    [No Abstract]   [Full Text] [Related]  

  • 29. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.
    Youdim MB; Buccafusco JJ
    J Neural Transm (Vienna); 2005 Apr; 112(4):519-37. PubMed ID: 15666041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Alzheimer drugs for mild cognitive impairment].
    Fellgiebel A
    Neuropsychiatr; 2007; 21(3):230-3. PubMed ID: 17915184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease.
    Robbins TW; McAlonan G; Muir JL; Everitt BJ
    Behav Brain Res; 1997 Feb; 83(1-2):15-23. PubMed ID: 9062655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
    O' Neill C
    Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
    Fariello RG
    Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
    [No Abstract]   [Full Text] [Related]  

  • 34. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
    García-Barroso C; Ricobaraza A; Pascual-Lucas M; Unceta N; Rico AJ; Goicolea MA; Sallés J; Lanciego JL; Oyarzabal J; Franco R; Cuadrado-Tejedor M; García-Osta A
    Neuropharmacology; 2013 Jan; 64():114-23. PubMed ID: 22776546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer's Disease Patients?
    Femminella GD; Leosco D; Ferrara N; Rengo G
    CNS Neurol Disord Drug Targets; 2016; 15(6):665-71. PubMed ID: 27189470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive Enhancement: Treating or Cheating?
    Whetstine LM
    Semin Pediatr Neurol; 2015 Sep; 22(3):172-6. PubMed ID: 26358427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognition enhancers between treating and doping the mind.
    Lanni C; Lenzken SC; Pascale A; Del Vecchio I; Racchi M; Pistoia F; Govoni S
    Pharmacol Res; 2008 Mar; 57(3):196-213. PubMed ID: 18353672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.
    Gualtieri F; Manetti D; Romanelli MN; Ghelardini C
    Curr Pharm Des; 2002; 8(2):125-38. PubMed ID: 11812254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?
    Lockhart BP; Lestage PJ
    Exp Gerontol; 2003; 38(1-2):119-28. PubMed ID: 12543269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nootropic and Anti-Alzheimer's Actions of Medicinal Plants: Molecular Insight into Therapeutic Potential to Alleviate Alzheimer's Neuropathology.
    Uddin MS; Al Mamun A; Kabir MT; Jakaria M; Mathew B; Barreto GE; Ashraf GM
    Mol Neurobiol; 2019 Jul; 56(7):4925-4944. PubMed ID: 30414087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.